There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Iterum Therapeutics (ITRM – Research Report) and Mainz Biomed B.V. (MYNZ – Research Report) with bullish sentiments.
Iterum Therapeutics (ITRM)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Iterum Therapeutics today and set a price target of $6.00. The company’s shares closed last Wednesday at $1.39.
According to TipRanks.com, Arce is a 5-star analyst with an average return of
Iterum Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.50.
See today’s best-performing stocks on TipRanks >>
Mainz Biomed B.V. (MYNZ)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Mainz Biomed B.V. today and set a price target of $3.00. The company’s shares closed last Wednesday at $0.92, close to its 52-week low of $0.85.
According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Mainz Biomed B.V. is a Moderate Buy with an average price target of $3.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ITRM:
- Iterum Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
- Biotech Alert: Searches spiking for these stocks today
- Iterum Shareholders Reject Board’s Share Issuance Proposal
- Iterum Therapeutics Announces Triumph in Phase 3 uUTI Trial
- Iterum Therapeutics Reports Positive Phase 3 Trial Results
